The FDA recommended (April 22, 2022) against their use in treatment of COVID-19 because Omicron has become the dominant variant in the United States, and the new circulating Omicron subvariants are resistant to their neutralizing activity (see NIH: Anti-SARS-CoV-2 Monoclonal Antibodies).